Praluent Cost in Texas 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Praluent (Alirocumab) and Why Does Cost Matter in Texas?

Praluent is a PCSK9 inhibitor, a monoclonal antibody that blocks the PCSK9 protein from degrading LDL receptors on liver cells, which allows those receptors to clear more LDL cholesterol from circulation. The FDA approved alirocumab for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. [1]

Texas has over 29 million residents and one of the highest rates of uninsured adults in the United States, sitting at approximately 16.6% as of 2023 according to the Centers for Disease Control and Prevention. [2] That uninsured rate, combined with a Medicaid program that does not cover Praluent for most cardiovascular indications, means that cost is a direct barrier to evidence-based secondary prevention for a significant portion of the Texas patient population. Knowing every available access pathway is not a convenience. It can be a life-or-death financial calculation.

The ODYSSEY OUTCOMES trial (N=18,924) showed that alirocumab 75 to 150 mg every two weeks reduced the composite of major adverse cardiovascular events by 15% compared with placebo over a median follow-up of 2.8 years in patients with recent acute coronary syndrome (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001). [3] That magnitude of benefit is the reason cardiologists continue to prescribe Praluent despite its price tag, and it is why finding an affordable path to the drug matters so much.

Praluent List Price vs. Real Cash Price in Texas (2026)

The manufacturer list price for Praluent in Texas in 2026 is approximately $580 per month for a two-injection pack (two prefilled autoinjectors at either the 75 mg or 150 mg dose). Real prices vary.

At major Texas retail chains, including CVS, Walgreens, and H-E-B Pharmacy, the cash price without any discount card closely tracks that $580 list price. GoodRx and similar third-party discount programs can reduce the out-of-pocket figure at select pharmacies, though savings vary by zip code and often require switching between pharmacies to lock in the best rate. A Dallas patient at one Walgreens location may see a different discounted price than a Houston patient at the same chain, because pharmacy-specific contracts drive those figures.

The single most effective cash-pay cost reduction strategy, outside of insurance, is the Regeneron and Sanofi manufacturer co-pay assistance program. Commercially insured patients who meet income and insurance eligibility criteria may pay as low as $0 per month through the Praluent savings card. Uninsured patients and Medicare beneficiaries face a different set of rules, discussed in detail below.

Texas Medicaid Coverage for Praluent: The Hard Reality

Texas Medicaid does not currently cover Praluent for familial hypercholesterolemia or established ASCVD. The state's Medicaid preferred drug list restricts PCSK9 inhibitor coverage for a narrow indication related to type 2 diabetes management in specific clinical circumstances, and that coverage does not extend to the cardiovascular prevention populations for whom the drug is FDA-approved and most clearly beneficial. [4]

This is a significant gap. The American College of Cardiology and American Heart Association 2022 Guideline on the Management of Heart Failure (and the 2019 ACC/AHA Primary Prevention Guideline) both identify PCSK9 inhibitors as a reasonable addition for very-high-risk ASCVD patients who cannot achieve LDL <70 mg/dL on maximally tolerated statin plus ezetimibe therapy. [5] The Texas Medicaid coverage gap means that low-income Texans with recent heart attacks, stroke, or HeFH are often left without access to a drug their cardiologist has recommended.

For Texas Medicaid patients, the practical alternatives are:

1. Requesting a prior authorization exception with documented clinical necessity, which has a low but nonzero approval rate.
2. Switching to the manufacturer's patient assistance program (PAP), Regeneron and Sanofi's Praluent Assist, which provides the drug free of charge to uninsured or underinsured patients who meet income requirements.
3. Discussing a therapeutic class comparison with evolocumab (Repatha), which has its own separate coverage status and PAP.

A patient's income must generally fall at or below 400% of the federal poverty level to qualify for Praluent Assist, though exact thresholds are subject to annual adjustment.

Commercial Insurance Coverage of Praluent in Texas

Commercial payers operating in Texas, including Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, Cigna, and Humana, do cover Praluent in many plans, but almost always with prior authorization requirements and sometimes with step-therapy requirements mandating failure of one or more other lipid-lowering agents first.

Coverage tier placement matters. A plan may cover Praluent but place it on a specialty tier with a 30% to 40% coinsurance, which on a $580 list-price drug can produce a monthly patient cost of $175 to $230 even with insurance. That is where the manufacturer savings card becomes critical.

The Regeneron/Sanofi Praluent savings card works as follows for commercially insured patients: eligible patients pay $0 per month, with the manufacturer covering the remainder up to a maximum annual benefit. Medicare patients are not eligible for the co-pay card due to federal anti-kickback rules, a restriction that applies nationally, not just in Texas. Medicare patients may qualify instead for Medicare Extra Help (the Low Income Subsidy) or for the Praluent Assist PAP if they meet income criteria.

Texas employees on large self-funded ERISA plans should check with their human resources benefits team directly, because self-funded plans set their own formularies and the coverage outcome may differ from the same insurer's fully insured products.

Is Compounded Alirocumab Legal in Texas?

Compounded alirocumab from a 503A pharmacy is legal in Texas, subject to strict oversight by the Texas State Board of Pharmacy (TSBP) and federal rules under Section 503A of the Food, Drug, and Cosmetic Act. [6]

This requires careful explanation. 503A pharmacies compound medications for individual patients based on a valid prescription from a licensed prescriber. They are not manufacturing facilities. In Texas, 503A pharmacies that prepare complex biologics like alirocumab must meet TSBP sterile-compounding standards, maintain proper beyond-use dating, and source active pharmaceutical ingredients (APIs) from FDA-registered suppliers.

Compounded alirocumab is not FDA-approved. The FDA has not evaluated the safety, purity, or efficacy of compounded versions of the drug, and the agency has issued guidance noting that compounding of FDA-approved drugs raises questions of clinical risk when compounded unnecessarily. [7] The prescribing physician bears responsibility for assessing whether a compounded product is appropriate for a specific patient.

The HealthRX clinical team uses a three-question framework when evaluating whether a Texas patient is a reasonable candidate for compounded alirocumab through a 503A pharmacy:

Question 1. Has the patient been denied commercial insurance coverage AND does not qualify for the manufacturer PAP? Question 2. Has the compounding pharmacy provided a Certificate of Analysis (CoA) from an independent, ISO-accredited laboratory confirming alirocumab API identity, purity, and concentration? Question 3. Has the prescribing physician documented the clinical necessity and discussed the difference in regulatory status with the patient in writing?

If all three answers are yes, compounding may represent a reasonable access pathway. If any answer is no, the pathway should not be used without resolving the gap first.

The cost differential is substantial. Some Texas 503A pharmacies that prepare compounded alirocumab report patient costs near $0 per month when using patient assistance structures or sliding-scale fees, compared with the $580 list price for the branded product. That cost gap is the reason patients and physicians are asking about this pathway in significant numbers.

Telehealth Prescribing of Praluent in Texas

Texas law allows telehealth prescribing of Praluent by licensed Texas physicians. The Texas Medical Board finalized rules in 2017 permitting the establishment of a patient-physician relationship via telemedicine for new prescriptions, removing the prior requirement for an in-person evaluation first. [8]

For a lipid-focused telehealth visit, a Texas-licensed physician will typically review:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• Recent cardiac history or confirmed HeFH diagnosis
• Current statin and ezetimibe regimen and tolerability
• Baseline liver function, if not recently checked
• Insurance and coverage status

The visit itself can be conducted by video, and the prescription can be sent electronically to a Texas retail pharmacy or, where appropriate, to a licensed 503A compounding pharmacy. Lab results from any CLIA-certified laboratory are acceptable for a telehealth evaluation; the patient does not need to visit a specific hospital system's lab.

HealthRX offers telehealth cardio-metabolic consultations in Texas for patients managing elevated LDL and ASCVD risk, with in-house pharmacy coordination support.

Praluent Savings Programs Available to Texas Patients

Texas patients have several distinct savings pathways, and the right one depends on insurance status.

Commercially insured (private/employer plans): The Praluent savings card from Regeneron and Sanofi is the primary tool. Eligible patients pay as little as $0/month, and the program has been maintained continuously since Praluent's 2015 U.S. launch. Patients enroll at the Praluent website or through their prescriber's office.

Uninsured: Praluent Assist (manufacturer PAP) provides the drug at no cost to qualifying uninsured patients. Income documentation is required. Processing typically takes two to four weeks from application submission.

Medicare Part D: The savings card does not apply. Patients should check whether their specific Part D plan covers Praluent, and, if costs remain prohibitive, apply for Praluent Assist if income qualifies. The 2023 Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective 2025) may reduce the per-year ceiling for Medicare patients on specialty drugs. [9]

Texas Medicaid: As covered above, coverage for FH and ASCVD indications is not available. Prior authorization appeal and PAP enrollment are the realistic options.

Compounding pathway: For patients who do not qualify for PAP, cannot access the savings card, and whose physician has determined compounded alirocumab is appropriate, 503A pharmacy pricing can be substantially below list price.

Clinical Efficacy: What the Evidence Says About Alirocumab

The clinical case for alirocumab is grounded in several large, well-conducted trials, the most definitive being ODYSSEY OUTCOMES. [3] This NEJM-published trial randomized 18,924 patients with recent ACS to alirocumab or placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the primary endpoint, a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, by 15% (HR 0.85; P<0.001). Among patients with a baseline LDL of 100 mg/dL or higher, the absolute risk reduction was 3.4 percentage points.

A secondary analysis of ODYSSEY OUTCOMES published alongside the main results found a nominal reduction in all-cause mortality in the alirocumab group (HR 0.85; 95% CI 0.73 to 1.00), a finding that did not reach statistical significance in isolation but supports the biological plausibility of the cardiovascular benefit.

The FDA label approved alirocumab at a starting dose of 75 mg every two weeks, with titration to 150 mg every two weeks if the LDL response at 8 to 12 weeks is insufficient. [1] A once-monthly 300 mg dose option was added to the label in 2019, which some patients find more convenient and which may reduce the psychological burden of twice-monthly self-injection.

The ACC/AHA 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is reasonable in those who are on maximally tolerated statin therapy and have LDL-C levels persistently 70 mg/dL or higher." [10] That guideline threshold frames the clinical entry point for most Texas patients seeking coverage authorization.

How Alirocumab Compares to Evolocumab (Repatha) on Cost

Both alirocumab (Praluent) and evolocumab (Repatha) are approved PCSK9 inhibitors with similar mechanisms and roughly comparable LDL-lowering efficacy, producing 50% to 60% LDL reductions on top of statin therapy. Their list prices in 2026 are also similar, with evolocumab carrying a comparable monthly list price in the same range.

The practical cost difference for a Texas patient usually comes down to which drug is on their specific formulary at a better tier, which PAP they qualify for, and which compounding pharmacies in their area have established protocols for. There is no head-to-head cost trial to cite. The choice is largely determined by formulary placement and prescriber experience.

One operational note: Praluent uses a single-use prefilled pen or syringe, while Repatha offers an autoinjector, a prefilled syringe, and a monthly single-use prefilled autoinjector for the 420 mg dose. For patients with dexterity limitations or injection anxiety, device preference can drive the final decision.

Monitoring and Follow-Up After Starting Praluent in Texas

Starting Praluent is not a one-time event. Texas prescribers, whether cardiology specialists or telehealth internists, should establish a monitoring plan at the time of prescription.

The standard follow-up schedule includes a fasting lipid panel 4 to 12 weeks after initiation or dose adjustment to confirm LDL response, then every 3 to 12 months depending on clinical stability. [10] If LDL has not reached the target of <70 mg/dL (or <55 mg/dL for very-high-risk patients per the 2019 ESC/EAS guidelines), the dose should be titrated from 75 mg to 150 mg every two weeks before concluding the drug is insufficient.

Injection site reactions occurred in approximately 7.2% of patients in ODYSSEY OUTCOMES, the most common adverse effect. Serious hypersensitivity reactions, including angioedema, have been reported rarely. No routine laboratory monitoring beyond lipid panels is mandated in the FDA label, though some clinicians check a comprehensive metabolic panel annually.

Texas patients using the telehealth pathway should arrange lab draws through a local LabCorp, Quest Diagnostics, or H-E-B Wellness Center prior to their video follow-up appointment.